The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR and inhibitors (antagonists) of sEH. The invention also provides methods for treating subjects suffering from diseases associated with FXR and sEH, such as metabolic disorders, in particular non-alcoholic fatty liver or nonalcoholic steatohepatitis (NASH).

Provided are an intermetallic compound having high stability and high activity, and a catalyst using the same. A hydrogen storage/release material containing an intermetallic compound represented by formula (1): RTX . . . (1) wherein R represents a lanthanoid element, T represents a transition metal in period 4 or period 5 in the periodic table, and X represents Si, Al or Ge.

Provided are an intermetallic compound having high stability and high activity, and a catalyst using the same. A hydrogen storage/release material containing an intermetallic compound represented by formula (1): RTX . . . (1) wherein R represents a lanthanoid element, T represents a transition metal in period 4 or period 5 in the periodic table, and X represents Si, Al or Ge.

Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.

Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.

The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention provides compounds, compositions thereof, and methods of using the same.

The present disclosure relates to compound (I) ##STR00001##
wherein R1 and R2 independently represent a hydrogen atom, a (C.sub.1-C.sub.4)alkoxy group, a fluoro(C.sub.1-C.sub.4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C.sub.1-C.sub.4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C.sub.1-C.sub.4)alkyl group, a CONHR6 group, a CONR7R8 group, a SO.sub.2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a (CH.sub.2).sub.nNR7R8 group or a hydroxy(C.sub.1-C.sub.4)alkyl group; R6 represents a hydrogen atom, a (CHR9).sub.m(CH.sub.2).sub.nNR7R8 group or a (C.sub.1-C.sub.6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.

The present disclosure relates to compound (I) ##STR00001##
wherein R1 and R2 independently represent a hydrogen atom, a (C.sub.1-C.sub.4)alkoxy group, a fluoro(C.sub.1-C.sub.4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C.sub.1-C.sub.4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C.sub.1-C.sub.4)alkyl group, a CONHR6 group, a CONR7R8 group, a SO.sub.2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a (CH.sub.2).sub.nNR7R8 group or a hydroxy(C.sub.1-C.sub.4)alkyl group; R6 represents a hydrogen atom, a (CHR9).sub.m(CH.sub.2).sub.nNR7R8 group or a (C.sub.1-C.sub.6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.

The present invention provides processes for the preparation of Apalutamide (1), as well as intermediates useful in the preparation thereof. In particular, the process of the invention utilizes the intermediate compound of Formula (2), wherein G is OH or a leaving group, which provides improvements over the known processes for the preparation of Apalutamide (1). ##STR00001##